These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32252973)

  • 1. [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
    Auditeau C; Talbot A; Blandinières A; Smadja DM; Gendron N
    Bull Cancer; 2020 May; 107(5):574-585. PubMed ID: 32252973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
    J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
    [No Abstract]   [Full Text] [Related]  

  • 3. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors.
    Grilusová K; Bolek T; Škorňová I; Staško J; Samoš M; Mokáň M
    Klin Onkol; 2021; 34(4):283-290. PubMed ID: 34905929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
    Arachchillage DR; Besser M; Maclean R; Baglin T; van Veen JJ
    Thromb Res; 2016 Jul; 143():137-40. PubMed ID: 27244105
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
    Yanagisawa D; Abe K; Amano H; Komatsuda S; Honda T; Manabe D; Yamamoto H; Kozuma K; Kodashima S; Asaoka Y; Yamamoto T; Tanaka A
    PLoS One; 2021; 16(11):e0260585. PubMed ID: 34843582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants: An update.
    Franco Moreno AI; Martín Díaz RM; García Navarro MJ
    Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
    Rojas-Hernandez CM; Oo TH
    Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Holden A; Azimi N; Forest CP
    JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants for use in paediatrics.
    Jaffray J; Young G
    Lancet Child Adolesc Health; 2022 Mar; 6(3):207-214. PubMed ID: 35033222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
    Gulba DC; Broscaru L
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):83-91. PubMed ID: 28144727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants: evidence and unresolved issues.
    Chan N; Sobieraj-Teague M; Eikelboom JW
    Lancet; 2020 Nov; 396(10264):1767-1776. PubMed ID: 33248499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
    Harenberg J
    Thromb Res; 2016 Apr; 140 Suppl 1():S165-7. PubMed ID: 27067972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
    Gue YX; Spinthakis N; Egred M; Gorog DA; Farag M
    Am J Cardiol; 2021 Mar; 142():147-151. PubMed ID: 33359200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.